Specifications
- Purity
- ≥98% (HPLC)
- Identity
- 1H-NMR
- Appearance
- White to off-white powder
Properties
- Solvents
- chloroform, acentonitrile
Available from stock
Ropivacaine
- SKU
- R0124
Category: API's & Intermediates
- Synonyms
- (S)-Ropivacaine , (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide
- 84057-95-4
- CAS-Number
- C17H26N2O
- Molecular Formula
- 274.40
- Molecular Weight
- Long Term Storage
- -20°C
- Use / Stability
- Stable for at least 2 years after receipt when stored at -20°C.
- Handling Advice
- Protect from light and moisture.
- Short Term Storage
- -20°C
- Shipping
- AMBIENT
- Transportation
- Not dangerous goods
- GHS Symbol
- GHS07
- Precautionary statements
- P301 + P312 + P330
- Hazard statements
- H302
- Description
- Ropivacaine is a long-acting amide local anaesthetic agent. Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers. It is a pure S(-)enantiomer and less lipophilic than racemic sodium channel blockers, such as bupivacaine and is less likely to penetrate large myelinated motor fibres, resulting in a relatively reduced motor blockade. Thus, ropivacaine has a greater degree of motor sensory differentiation, which could be useful when motor blockade is undesirable. The reduced lipophilicity is also associated with decreased potential for central nervous system toxicity and cardiotoxicity.
- References
- (1) R.D. Wang, et al., Exp. Opin. Pharmacother. 2, 2051 (2001) (Review) , (2) T.G. Hansen, Exp. Rev. Neurother. 4, 781 (2004) (Review) , (3) G. Kuthiala & G. Chaudhary, Indian J. Anaesth. 55, 104 (2011) (Review)
- InChi Key
- ZKMNUMMKYBVTFN-UHFFFAOYSA-N
- Smiles
- CC1=CC=CC(C)=C1NC(C2CCCCN2CCC)=O
Ropivacaine is a long-acting amide local anaesthetic agent. Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers. It is a pure S(-)enantiomer and less lipophilic than racemic sodium channel blockers, such as bupivacaine and is less likely to penetrate large myelinated motor fibres, resulting in a relatively reduced motor blockade. Thus, ropivacaine has a greater degree of motor sensory differentiation, which could be useful when motor blockade is undesirable. The reduced lipophilicity is also associated with decreased potential for central nervous system toxicity and cardiotoxicity.
Additional information
| Synonyms | (S)-Ropivacaine, (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide |
|---|---|
| Purity | ≥98% (HPLC) |
| Appearance | White to off-white powder |
| CAS-Number | 84057-95-4 |
| Molecular Formula | C17H26N2O |
| Molecular Weight | 274.40 |
| Identity | 1H-NMR |
| Solvents | chloroform, acentonitrile |
| Smiles | CC1=CC=CC(C)=C1NC(C2CCCCN2CCC)=O |
| InChi Key | ZKMNUMMKYBVTFN-UHFFFAOYSA-N |
| Shipping | AMBIENT |
| Short Term Storage | -20°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Hazard statements | H302 |
| Precautionary statements | P301 + P312 + P330 |
| GHS Symbol | GHS07 |
| Transportation | Not dangerous goods |
| References | (1) R.D. Wang, et al., Exp. Opin. Pharmacother. 2, 2051 (2001) (Review), (2) T.G. Hansen, Exp. Rev. Neurother. 4, 781 (2004) (Review), (3) G. Kuthiala & G. Chaudhary, Indian J. Anaesth. 55, 104 (2011) (Review) |
| Quantity | 50 mg, 250 mg, Bulk |
